Human AFP-L3(Alpha-fetoprotein Lens culinaris agglutiin 3) ELISA Kit

Name: Human AFP-L3(Alpha-fetoprotein Lens culinaris agglutiin 3) ELISA Kit
SKU: DEIA-BJ15
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

serum, plasma, tissue homogenates and other biological fluids.

Species Reactivity

Human

Detection Method

sELISA

Intended Use

For quantitative detection of AFP-L3 in serum, plasma, tissue homogenates and other biological fluids.

Contents of Kit

Storage

2-8°C (for sealed box), please do not freeze! See kit label for expiry date

Performance Characteristics

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% within the expiration date under appropriate storage condition.

To minimize extra influence on performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is strongly suggested that the same operator performs the whole assay from the beginning to the end.

Precision

Intra-Assay: CV<8%
Inter-Assay: CV<10%

Detection Range

0.625-40ng/ml

Sensitivity

0.375ng/ml

Standard Curve

Results of a typical standard operation of a AFP-L3 ELISA Kit are listed below. This standard curve was generated at our lab for demonstration purpose only. Users shall obtain standard curve as per experiment by themselves. (N/A=not applicable)

Citations

Have you cited DEIA-BJ15 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

A case of alpha-fetoprotein-producing gastric cancer

ANNALS ACADEMY OF MEDICINE SINGAPORE

Authors: Foo, KF; Tan, CK; Wong, KKY; Hong, GS; Ngan, BY

Abstract

Introduction: A case of alpha-fetoprotein (AFP)-producing gastric cancer is described in a 57-year-old Chinese woman. Clinical Picture: She presented with bleeding tendency and bone pain, and was found to have haematological evidence of disseminated intravascular coagulation and spinal metastasis. Her tumour markers, including AFP, Ca 19-9 and carcinoembryonic antigen (CEA) were elevated. In view of the elevated tumour markers, there was an exhaustive search for a primary lesion in the gastrointestinal tract, liver and ovaries. There was no radiological evidence to suggest any lesion in the chest, liver or pelvis. Lectin affinity electrophoresis of the AFP showed AFP-L2 and AFP-L3 bands, which are suggestive of a non-hepatoma malignancy. Management : Gastroscopy showed a gastric ulcer and she developed bleeding after the gastric biopsy which required urgent surgery. Intraoperatively she was found to have carcinomatous peritonei and a malignant ulcer in the greater curve of the stomach. Histology confirmed a linitis plastica like adenocarcinoma which stains for AFP. Outcome: She died from multi-organ failure 3 days after surgery. Conclusion: AFP-producing adenocarcinoma of the stomach is not uncommon. Lectin affinity electrophoresis of AFP is helpful in the differentiation between hepatoma and non-hepatoma malignancies.

Highly sensitive lens culinaris agglutinin-reactive alpha-fetoprotein is useful for early detection of hepatocellular carcinoma in patients with chronic liver disease

ONCOLOGY REPORTS

Authors: Oda, Kohei; Ido, Akio; Tamai, Tsutomu; Matsushita, Masakaze; Kumagai, Kotaro; Mawatari, Sei-Ichi; Saishoji, Akiko; Kure, Takeshi; Ohno, Kaori; Toyokura, Eriko; Imanaka, Dai; Moriuchi, Akihiro; Uto, Hirofumi; Oketani, Makoto; Hashiguchi, Teruto; Tsubouchi, Hirohito

Abstract

The fucosylated fraction of alpha-fetoprotein (AFP-L3) is a specific marker for hepatocellular carcinoma (HCC). However, conventional AFP-L3% (c-AFP-L3%) has not always been reliable in cases with low serum alpha-fetoprotein (AFP) levels. In this study, we evaluated the clinical utility of a newly developed assay, highly sensitive AFP-L3% (hs-AFP-L3%). Subjects included 74 patients with benign liver disease (BLD), including chronic hepatitis and cirrhosis, and 94 with HCC. Serum hs-AFP-L3% was significantly higher than c-AFP-L3% in patients with early-stage HCC (solitary or <20 mm in diameter). Additionally, hs-AFP-L3% was significantly increased in patients with well-differentiated HCC. In patients with serum AFP <20 ng/ml, the sensitivities of c-AFP-L3% and hs-AFP-L3% were 12.5 and 44.6%, respectively, at a cut-off value of 5%. In 59 BLD patients with serum AFP <20 ng/ml, the HCC-positive rate in patients with hs-AFP-L3% >= 5% was significantly higher compared to those with hs-AFP-L3% <5% during the follow-up period (median, 35 months; range, 5-48 months). Importantly, none of the BLD patients with both serum AFP <20 ng/ml and hs-AFP-L3% <5% developed HCC. These results indicated that hs-AFP-L3% is useful for early detection of HCC in BLD patients, even for those with serum AFP <20 ng/ml. Furthermore, since hs-AFP-L3% increases before HCC is detectable by various advanced imaging modalities, this assay may help identify BILD patients with a higher risk of HCC.